Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion has corrected its US plant expansion plan to a single-batch 75,000L expansion (securing a total capacity of 141,000L) to respond to US pharmaceutical tariff policies and expand its CMO business.
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Future Business and Management Plan (Fair Disclosure) (Correction)
- Original Filing & Correction Date: November 19, 2025 / March 24, 2026
- Reason for Correction: Finalization of production facility expansion scale
- Key Corrected Expansion Plan:
- Expansion Strategy: (Before) Phased expansion of 66,000L (33,000L x 2 phases) to reach 132,000L total capacity → (After) Single-batch expansion of 75,000L to secure 141,000L total production capacity
- Plan Description: Additional facility investment plan for US plant to address US pharmaceutical tariff policies
- Investment Objectives: Countering US drug tariff policies, meeting growing product pipeline demand, and expanding CMO business
- Estimated Investment Amount: Up to KRW 700.0B
- Future Considerations: Potential construction of a new plant using idle land within the US plant site depending on future tariff policies and pipeline expansion
- Expected Effects: Mitigation of US drug tariffs and enhancement of corporate and shareholder value through mid-to-long term strategies
- Board Resolution / Information Date: November 19, 2025
- Investment Caution: Contains forward-looking guidance subject to shifts in business conditions and management plans.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of US Plant Expansion Progress and Facility Investment Filings
This corrected disclosure reflects the finalization of Celltrion’s US facility expansion scale to a single 75,000L phase (totaling 141,000L), making it important to monitor subsequent regulatory disclosures regarding the execution of the up to KRW 700.0B facility investment. Tracking capital expenditure and construction milestones ensures that capacity expansion aligns with the updated plan for tariff response and CMO expansion. Progress can be verified through future disclosures on new facility investments or under ‘Status of Facility Investment’ in upcoming periodic filings (Quarterly, Half-Yearly, or Annual Business Reports).
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
